世界の外分泌膵機能不全（EPI）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2269 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、外分泌膵機能不全（EPI）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療、診断（血液検査、内視鏡超音波検査、磁気共鳴画像法（MRI）、CTスキャン））、用途別市場規模（病院、外来手術センター、専門クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・外分泌膵機能不全（EPI）の市場動向 ・企業の競争状況、市場シェア ・外分泌膵機能不全（EPI）の種類別市場規模（治療、診断（血液検査、内視鏡超音波検査、磁気共鳴画像法（MRI）、CTスキャン）） ・外分泌膵機能不全（EPI）の用途別市場規模（病院、外来手術センター、専門クリニック） ・外分泌膵機能不全（EPI）の北米市場規模2016-2027（アメリカ、カナダ） ・外分泌膵機能不全（EPI）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・外分泌膵機能不全（EPI）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・外分泌膵機能不全（EPI）の中南米市場規模2016-2027（メキシコ、ブラジル） ・外分泌膵機能不全（EPI）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie、Allergan、Nordmark Arzneimittel、Digestive Care、Janssen Pharmaceuticals、Cilian、Anthera Pharmaceuticals、AzurRx Biopharma） ・結論

Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.

Market Analysis and Insights: Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size is projected to reach US$ 4593.9 million by 2026, from US$ 3460.6 million in 2019, at a CAGR of 4.1% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market.

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Scope and Market Size
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)

Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Therapeutics
1.2.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
1.3 Market by Application
1.3.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Perspective (2016-2027)
2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Industry Dynamic
2.3.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Trends
2.3.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Drivers
2.3.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Challenges
2.3.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue
3.4 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2020
3.5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027)

5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2016-2027)
6.2 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type
6.2.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2027)
6.3 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application
6.3.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2027)
6.4 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country
6.4.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2016-2027)
7.2 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type
7.2.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2027)
7.3 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application
7.3.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2027)
7.4 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country
7.4.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type
8.2.1 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application
8.3.1 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region
8.4.1 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2016-2027)
9.2 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type
9.2.1 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application
9.3.1 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country
9.4.1 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type
10.2.1 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application
10.3.1 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country
10.4.1 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.1.4 AbbVie Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Allergan
11.2.1 Allergan Company Details
11.2.2 Allergan Business Overview
11.2.3 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.2.4 Allergan Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.2.5 Allergan Recent Development
11.3 Nordmark Arzneimittel
11.3.1 Nordmark Arzneimittel Company Details
11.3.2 Nordmark Arzneimittel Business Overview
11.3.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.3.4 Nordmark Arzneimittel Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.3.5 Nordmark Arzneimittel Recent Development
11.4 Digestive Care
11.4.1 Digestive Care Company Details
11.4.2 Digestive Care Business Overview
11.4.3 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.4.4 Digestive Care Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.4.5 Digestive Care Recent Development
11.5 Janssen Pharmaceuticals
11.5.1 Janssen Pharmaceuticals Company Details
11.5.2 Janssen Pharmaceuticals Business Overview
11.5.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.5.4 Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.5.5 Janssen Pharmaceuticals Recent Development
11.6 Cilian
11.6.1 Cilian Company Details
11.6.2 Cilian Business Overview
11.6.3 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.6.4 Cilian Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.6.5 Cilian Recent Development
11.7 Anthera Pharmaceuticals
11.7.1 Anthera Pharmaceuticals Company Details
11.7.2 Anthera Pharmaceuticals Business Overview
11.7.3 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.7.4 Anthera Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.7.5 Anthera Pharmaceuticals Recent Development
11.8 AzurRx Biopharma
11.8.1 AzurRx Biopharma Company Details
11.8.2 AzurRx Biopharma Business Overview
11.8.3 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.8.4 AzurRx Biopharma Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
11.8.5 AzurRx Biopharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Therapeutics
Table 3. Key Players of Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Table 4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2016-2021)
Table 8. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Table 10. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Trends
Table 11. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Drivers
Table 12. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Challenges
Table 13. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Restraints
Table 14. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Players (2016-2021)
Table 16. Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics as of 2020)
Table 17. Ranking of Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Solution and Service
Table 21. Date of Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Table 25. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
Table 29. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 61. AbbVie Company Details
Table 62. AbbVie Business Overview
Table 63. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 64. AbbVie Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 65. AbbVie Recent Development
Table 66. Allergan Company Details
Table 67. Allergan Business Overview
Table 68. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 69. Allergan Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 70. Allergan Recent Development
Table 71. Nordmark Arzneimittel Company Details
Table 72. Nordmark Arzneimittel Business Overview
Table 73. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 74. Nordmark Arzneimittel Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 75. Nordmark Arzneimittel Recent Development
Table 76. Digestive Care Company Details
Table 77. Digestive Care Business Overview
Table 78. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 79. Digestive Care Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 80. Digestive Care Recent Development
Table 81. Janssen Pharmaceuticals Company Details
Table 82. Janssen Pharmaceuticals Business Overview
Table 83. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 84. Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 85. Janssen Pharmaceuticals Recent Development
Table 86. Cilian Company Details
Table 87. Cilian Business Overview
Table 88. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 89. Cilian Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 90. Cilian Recent Development
Table 91. Anthera Pharmaceuticals Company Details
Table 92. Anthera Pharmaceuticals Business Overview
Table 93. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product
Table 94. Anthera Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 95. Anthera Pharmaceuticals Recent Development
Table 96. AzurRx Biopharma Company Details
Table 97. AzurRx Biopharma Business Overview
Table 98. AzurRx Biopharma Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 99. AzurRx Biopharma Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. Therapeutics Features
Figure 3. Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning) Features
Figure 4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Ambulatory Surgical Centers Case Studies
Figure 7. Specialty Clinics Case Studies
Figure 8. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Report Years Considered
Figure 9. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2027
Figure 12. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Figure 13. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Players in 2020
Figure 14. Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2020
Figure 16. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Figure 17. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027)
Figure 18. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 20. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 21. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 22. United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 26. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 27. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 28. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Region (2016-2027)
Figure 38. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 46. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 47. Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 48. Mexico Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 54. Turkey Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. AbbVie Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 58. Allergan Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 59. Nordmark Arzneimittel Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 60. Digestive Care Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 61. Janssen Pharmaceuticals Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 62. Cilian Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 63. Anthera Pharmaceuticals Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 64. AzurRx Biopharma Revenue Growth Rate in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

---